Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: Three of the other five patients are in either a serious or a critical condition in hospital, while the remaining two have mild symptoms, the United Nations health agency said in a disease outbreak update. H7N9 bird flu emerged last year in China and has infected around 150 people so far there and in Taiwan and Hong Kong, killing at least 46 of them. The latest death was a 38-year-old man from China’s Fujian Province who became ill with H7N9 on January 3, was admitted to hospital on January 8 but died 2 days later. He had underlying illnesses, including tuberculosis and pneumoconiosis. China’s state news agency Xinhua reported another death from H7N9 in the southwestern Guizhou province on Monday, but this has yet to be confirmed by the WHO. A 65-year-old man infected with H7N9 also died in Hong Kong, the government said on Monday. The WHO reiterated there is no evidence as yet of any easy or sustained person-to-person transmission of the strain, and that the source of the human infections is still under investigation. Researchers in the United States said last month that while it is not impossible that H7N9 could become easily transmissible between people, it would need to undergo multiple mutations to do that. Scientists around the world are keeping a watchful eye, on alert for any sign the virus might develop that potential and start to spread rapidly. Claim: Death toll from new China bird flu rises: WHO.

A: Six more people in China have been confirmed as infected with the new H7N9 strain of bird flu and one of them has died, the World Health Organisation (WHO) said on Monday.
****
Q: Paragraph: Although Pfizer continues to test the drug, called dacomitinib, in another Phase III study, hopes for its success have now largely faded, according to ISI Group analyst Mark Schoenebaum. “We believe consensus expectations (for the drug) will be close to zero given today’s readout” of unsuccessful trial results, Schoenebaum said in a research note. In one of the failed trials, called ARCHER 1009, patients given Pfizer’s once-daily pill did not show improved survival without the cancer worsening, compared with Roche Holding AG’s widely used Tarceva (erlotinib). Tarceva is the current standard of care in patients with mutated forms of a protein called Epidermal Growth Factor Receptor (EGFR). The protein plays a role in normal regulation of cell growth, but when mutated is believed to cause cells to proliferate and thereby help spur various types of cancer. Dacomitinib is designed to block several types of Epidermal Growth Factor receptors, while Tarceva and similar treatments for lung cancer target only one type of receptor. Cowen and Co had forecast annual sales of $500 million by 2020 for dacomitinib, if it were approved for lung cancer. That would make it a moderate-sized product for Pfizer, the largest U.S. drugmaker, which has annual revenue of $50 billion. Schoenebaum said there has been little investor interest in the drug and that Wall Street had expected it to generate annual sales of only $300 million by 2018. The second failed trial, named BR.26, involved patients that previously had failed to benefit from chemotherapy as well as from treatment with an EGFR inhibitor. Overall survival of patients taking the Pfizer drug was not prolonged in the study, compared with patients given a placebo. Pfizer said adverse events seen with dacomitinib were consistent with those seen in smaller earlier studies. In the meantime, Pfizer said dacomitinib is also being tested in a third late-stage trial, called ARCHER 1050, among patients with advanced non-small cell lung cancer who have not received prior treatment. The study will compare dacomitinib with Iressa (gefitinib), an EGFR inhibitor sold by AstraZeneca Plc. Results from that study are expected in 2015. Pfizer shares were little changed in morning trading on the New York Stock Exchange. Claim: Pfizer lung cancer drug fails in two large studies.

A: Pfizer Inc on Monday said one of its experimental drugs had failed to meet its goals in two late-stage studies among patients who had received prior treatment for advanced non-small cell lung cancer, the most common form of the disease.
****
Q: Paragraph: Lt. Gen. Todd Semonite on Thursday approved the plan to install defenses at the Brandon Road Lock and Dam near Joliet, Illinois, about 40 miles from Lake Michigan. The site is a crucial choke point in an aquatic pathway between the lake and the carp-infested Illinois River. The plan represents a compromise between proposals to erect barriers that would seal off Lake Michigan from the river and less drastic measures such as stepped-up commercial fishing. Environmentalists and states including Michigan had argued for physical separation, while Illinois and Indiana contended that it would disrupt cargo shipping and that a Chicago-area electric barrier was keeping the carp at bay. Although only a few live Asian carp have been found past the barrier, the fish’s DNA has turned up there as recently as April, when water samples were taken from Chicago’s Lake Calumet. The Corps says the leading edge of adult bighead and silver carp — the most feared of several Asian species because they gorge on plankton that other fish need — is about four miles from the Brandon Road complex. “The Brandon Road project is the only shot we have to get additional protections in place to stop the carp,” said Marc Smith of the National Wildlife Federation. “It will significantly reduce the risk.” The plan calls for installing a gantlet of technologies intended to repel approaching fish, including additional electric barriers and underwater speakers that would blast loud noises, plus an “air bubble curtain.” A specially designed “flushing lock” would wash away carp that might be floating on the water as vessels pass through. Semonite’s endorsement came more than five years after the Army Corps offered a series of options for blocking the carp’s advance. It’s now up to Congress to decide whether to authorize the project and provide most of the funding. A pending House bill recommends $3.8 million for preconstruction, engineering and design work in 2020. The expected completion date is March 2027. “With the Asian Carp on the doorstep of our region’s most vital natural resource, we have a small window of time to stop this invasive species before it inflicts irreparable damage on our Great Lakes and our $7 billion fishing industry and equally important tourism industry,” said Rep. Marcy Kaptur, an Ohio Democrat who chairs the Appropriations Subcommittee on Energy and Water Development. Republican Reps. Paul Mitchell and Bill Huizenga of Michigan also pledged support. Bipartisan teamwork will be essential, particularly given the plan’s escalating cost, said Molly Flanagan of the Alliance for the Great Lakes. A draft released in 2017 estimated that the project would cost $275 million. The final version put the price tag at $778 million, and that would be under an “expedited” scenario in which the various technologies would be installed at the same time. It could reach $832 million under an alternative “phased” strategy, spokesman Allen Marshall said. Another key will be getting financial support from Great Lakes states. The Army Corps generally requires non-federal partners to pay 35 percent of a project’s construction costs, although Congress could waive some or all of the requirement. Illinois Gov. J.B. Pritzker last month authorized his state’s cooperation with initial phases of the program but said he wouldn’t commit to long-term support without efforts to limit costs and contributions from other states. Sens. Dick Durbin and Tammy Duckworth, both Illinois Democrats, said Friday that they would seek congressional approval “under a cost-share agreement that will ensure Illinois isn’t left footing the bill for a project that will benefit the entire Great Lakes region.” ___ Follow John Flesher on Twitter: http://twitter.com/johnflesher Claim: Army Corps approves $778M plan to block Asian carp advance.

A:
The head of the Army Corps of Engineers has sent Congress a $778 million plan to fortify an Illinois waterway with noisemakers, electric cables and other devices in the hope that they will prevent Asian carp from reaching the Great Lakes, where the aggressive invaders could leave other fish with too little to eat.
****